XW143E7Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7

  • Billable / Specific Code
ICD-10-PCS XW143E7
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW143E7 is a billable ICD-10-PCS procedure code for Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Transfusion involves putting in blood or blood products.

Code Identity

ICD-10-PCS Code
XW143E7
Billable Status
Yes — Valid for Submission
Code Describes
Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7
Parent Code
Short Description
Transfuse Hyprimun Globln in Central Vein, Perc, New Tech 7

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation1Transfusion
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyEHyperimmune Globulin
7Qualifier7New Technology Group 7

Code History

Replaces previously assigned code(s):
  • 30243S1 — Transfuse Nonaut Globulin in Central Vein, Perc

Similar Procedure Codes

Questions About XW143E7

Is XW143E7 a billable code?

Yes. XW143E7 is a complete seven-character ICD-10-PCS code, specific enough to report Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW143E7 mean?

XW143E7 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 1 is the Operation (Transfusion); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character E is the Device/Substance/Technology (Hyperimmune Globulin); the 7th character 7 is the Qualifier (New Technology Group 7).